Cidara Therapeutics, Inc. CDTX 深 滬
已收盤 01-07 16:00:00 美东时间
221.38
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 221.38
- 總市值 56.14亿
- 52周最高 221.42
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 15.22
- 委 比 0.00%
- 總股本 2535.81万
- 歷史最高 382.60
- 量 比 0
- 振 幅 0.00%
- 歷史最低 8.00
- 每 手 1
- 風險率 66.42%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多不再迷惘的制药商：2025年并购额暴涨124%，巨头狂扫创新药资产
那些关于药品定价政策及可能侵蚀利润的关税措施的最坏担忧均未成真，行业焦虑情绪得到明显缓解。 智通财经APP获悉，下周，制药商们将赴旧金山出席摩根大通医疗健康年...
01-10 00:49
不再迷惘的制药商：2025年并购额暴涨124%，巨头狂扫创新药资产
下周，制药商们将赴旧金山出席摩根大通医疗健康年会，心态较2025年显著放松。回溯一年前，他们还对美国总统唐纳德·特朗普的政策走向感到困惑迷惘;如今，此前笼罩的诸...
01-09 21:50
Merck completes cash tender offer for Cidara Therapeutics
Merck (MRK) has finished its cash tender offer for all outstanding shares of Cidara Therapeutics (CDTX) at a price of $221.50 per Cidara share. The deal, announced in November, has a value of $9.2B. M...
01-07 20:28
Merck Completes Cash Tender Offer At Purchase Price Of $221.50 Per Share Of Common Stock Of Cidara Therapeutics
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, for all the outstanding shares of common stock of Cidara
01-07 19:55
Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study
Decoy Therapeutics, a subsidiary of Salarius Pharmaceuticals, is developing influenza fusion inhibitors using its IMP3ACT platform, showing strong binding affinity to viral targets. Collaborating with Texas Biomed, they conduct in vitro testing across influenza strains, including H5N1. The IMP3ACT platform leverages AI and rapid synthesis to design broad-spectrum antivirals targeting influenza, COVID, and RSV. Salarius aims to address global resp...
2025-12-01 13:00
Cidara Therapeutics Reaches Target Enrollment Of Phase 3 ANCHOR Trial Evaluating CD388
Target enrollment of 6,000 participants completed in the Northern HemispherePlanned interim analysis in Q1 2026 will determine potential need for additional enrollment during Southern Hemisphere flu season
2025-11-24 21:08
Pfizer's New mRNA Flu Vaccine Outperforms Traditional Shot Against Predominant Strains
Pfizer-funded study finds a next-gen mRNA flu shot works better against current strains — but causes more short-term side effects.
2025-11-21 23:48
Merck gets EU nod for subcutaneous version of Keytruda
Merck (MRK) has received approval from the European Commission for a subcutaneous injectable version of Keytruda (pembrolizumab), its anti-PD-1 therapy, for all adult indications. The subcutaneous in...
2025-11-19 22:20
Merck HIV therapy matches Gilead’s Biktarvy in late-stage trial
Merck (MRK) announced on Wednesday that its single-tablet antiviral regimen, doravirine and islatravir for adults with HIV, was found to be non-inferior to Gilead’s (GILD) once-daily HIV pill Biktarvy...
2025-11-19 20:27
Merck raises quarterly dividend by 4.9% to $0.85/share
Merck (MRK) declares $0.85/share quarterly dividend, 4.9% increase from prior dividend of $0.81. Forward yield 3.54% Payable Jan. 8; for shareholders of record Dec. 15; ex-div Dec. 15. See MRK Dividen...
2025-11-19 00:36
